Eating Disorders in AdolescenceDIAB-EDNCT07534059
Impact of Eating Disorders
An observational study of Eating Disorders in Adolescence, run by University Hospital, Rouen at 1 site in France.
Trial summary
Eating disorders (EDs), as classified by the American Psychiatric Association's DSM-5, have an estimated lifetime prevalence of 0.6% in the Caucasian adult population, with a male-to-female ratio of 1:8, and begin in 84% to 87% of cases between the ages of 15 and 25. Read more about this study
- Who is it for?
- Ages 18 to 40 years, women only
- Conditions the study is for
- Eating Disorders in Adolescence
- How many people
- 70 participants
- Where
- 1 siteFrance
- Study dates
- 10 Jun 2022to 1 Jun 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 40 years
- Women only
- No healthy volunteers
- Adult
Study population: type 1 diabetic patients
Who may be able to join
- Female patients
- Patients aged 18 to 40 years
- Patients diagnosed with type 1 diabetes (positive for anti-GAD, anti-IA2, and anti-ZnT8 antibodies)
- Patients on insulin therapy alone (basal-bolus regimen or insulin pump)
- Patients using a continuous glucose monitoring device such as an FSL or DEXCOM
- Patients followed in the clinical nutrition and/or diabetology department of the Rouen University Hospital and the Le Havre Hospital
- Social security coverage
- Patients who have agreed to participate in the study
Who cannot join
- Patients taking antidiabetic medication other than insulin therapy alone
- Patients with limited understanding of spoken or written French
- Individuals deprived of their liberty by an administrative or judicial decision, or individuals subject to legal protection measures for adults
- Individuals under guardianship, conservatorship, or other protective supervision
- Pregnant or breastfeeding women
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Impact of Eating Disorders on the Glycemic Profile of Type 1 Diabetic Patients
Eating disorders (EDs), as classified by the American Psychiatric Association's DSM-5, have an estimated lifetime prevalence of 0.6% in the Caucasian adult population, with a male-to-female ratio of 1:8, and begin in 84% to 87% of cases between the ages of 15 and 25.
Anorexia nervosa (AN) is an eating disorder that represents a significant public health concern due to its impact on long-term morbidity and mortality. The incidence of AN is steadily increasing in many countries, particularly in France, with a prevalence of 2-3% among adolescents and young adults. A 10-year mortality rate of 5-10% has been reported, making AN the psychiatric disorder with the highest mortality rate. This predominantly female disorder (female-to-female ratio of 1:9) is defined by the persistent association of disordered eating behavior, distorted body image, and obsessions with weight and food, with detrimental health consequences. Anorexia nervosa (AN) exposes patients to numerous somatic and neuropsychiatric complications, which are poor prognostic factors. Its etiopathogenesis is multifactorial and involves environmental, psychological, genetic, and sociocultural factors. Bulimia nervosa (BN) is also associated with an intense fear of gaining weight. There is a disturbance of body image characterized by profound dissatisfaction with weight and physical appearance. BN is characterized by binge-eating episodes (consuming a large amount of food in a short period of time, associated with a feeling of loss of control) followed by inappropriate compensatory behaviors such as self-induced vomiting, misuse of laxatives, diuretics, or other medications; fasting; and excessive exercise. Individuals with bulimia nervosa generally have a subnormal body mass index (BMI), making diagnosis more difficult.
Read more
Type 1 diabetes is an autoimmune disease characterized by the destruction of the beta cells of the pancreatic islets of Langerhans, leading to a deficiency in insulin secretion. Generally, the diagnosis is made in childhood or adolescence, but late-diagnosed forms exist, forming an entity called latent autoimmune diabetes in adults (LADA), also known as type 1 diabetes. Diagnosis is made by measuring antibodies specific to type 1 diabetes: anti-GAD and anti-IA2 antibodies as the first-line tests, and anti-ZnT8 antibodies as a second-line test. Drug treatment primarily relies on continuous insulin administration via multiple daily injections or an insulin pump. Nutritional management is a cornerstone of treatment, playing a crucial role in glycemic control and the prevention of metabolic complications.
"Diabulimia" is a recent term describing a specific eating disorder in patients with type 1 diabetes. It is characterized by a voluntary restriction of insulin administration for the purpose of weight loss, at the expense of optimal glycemic control. This condition involves several complex factors (such as insulin injection, capillary blood glucose, emotions, and body image) that link diabetes management to the patient's mental health.
"Diabulimia" is not yet recognized as a distinct medical entity, lacks precise diagnostic criteria, and is difficult to detect. However, the serious consequences it entails, such as diabetic ketoacidosis in the short term and the chronic complications of hyperglycemia in the long term, make its screening essential.
Read the detailed description
Technological advances in the treatment of type 1 diabetes have been significant in recent years and have considerably improved the management of the disease.
Continuous glucose monitoring has radically changed the management of type 1 diabetes by empowering patients to self-manage and adjust their insulin therapy. Glucose monitoring methods have evolved considerably over the last few decades: from urine tests before the 1980s, to capillary blood glucose self-monitoring with a portable blood glucose meter introduced in 1978, to continuous glucose monitoring (CGM) methods that emerged in 1999.
Recently, CGMs have replaced capillary blood glucose meters. CGMs include sensors and transmitters that send blood glucose readings to a receiving system such as a meter, smartphone, or smartwatch, and potentially to a cloud service.
Currently in France, all diabetic patients on multi-injection or continuous insulin pump administration are eligible for reimbursement of a continuous glucose monitoring system allowing the measurement of interstitial glucose by wearing an interstitial glucose sensor. This study aims to evaluate blood glucose readings collected by two devices:
- Abbott FreeStyle Libre (FSL) is a flash interstitial glucose monitoring system where glucose is continuously monitored via intermittent scanning (ISGS). It is a standalone interstitial glucose sensor that collects glucose data by scanning the sensor.
- Dexcom is a real-time continuous glucose monitoring (RTGS) system. The reader provides a blood glucose reading every 5 minutes, along with a trend arrow and data collection over several hours (up to 24 hours).
These continuous glucose monitoring (CGM) methods allow blood glucose readings to be transmitted to an online platform that healthcare professionals can access. They can then analyze these readings remotely. This data analysis is assisted by algorithms that identify the time spent within, above, or below the target blood glucose level. Following the assessment by the healthcare professional, the patient can be contacted directly via the platform's instant messaging service.
In recent years, a link has been observed between type 1 diabetes (T1D) and eating disorders (EDs). Indeed, patients with T1D are at higher risk of developing an ED than the general population. This is partly explained by the fact that particular attention is paid to the dietary and nutritional management of T1D patients from the moment of their diabetes diagnosis, in order to allow for better glycemic control. Eating disorders in patients with type 1 diabetes (T1D) can lead to potentially serious complications. In the short term, they increase the likelihood of diabetic ketoacidosis resulting from hyperglycemia not corrected by adequate insulin administration. Hospitalization rates and length of stay are also significantly higher in patients with both T1D and an eating disorder. In the long term, they can lead to a higher prevalence of microvascular complications such as diabetic retinopathy (with a 2.5-fold increased risk), microalbuminuria, and diabetic neuropathy. Higher mortality has also been demonstrated in these patients: a mortality rate of 4.06% for patients with T1D, 8.86% for patients with anorexia nervosa, and 14.5% for patients with both conditions.
Few studies have investigated the association between T1D and eating disorders. These studies are older, have small sample sizes, and focus on only one type of eating disorder. Within the framework of this project, the SCOFF questionnaire will be used to screen for restrictive (anorexia nervosa) and compulsive (bulimia) eating disorders. Glycemic control will be assessed through the analysis of CGM data. No study has used this innovative tool to evaluate the impact of eating disorders on type 1 diabetes.
The aim is also to change healthcare professionals' approach to eating disorders by screening for them regularly and early to prevent chronicity and short- and medium-term complications. These results could contribute to establishing specific recommendations regarding the screening for eating disorders in the management of patients with type 1 diabetes, and for appropriate multidisciplinary care.
- Conditions
- Eating Disorders in Adolescence
- Keywords
- type 1 diabetic patients
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Evaluate the impact of TCA on the glycemic profile of type 1 diabetic patients with eating disorder | Correlation of self-documented questionnaires completed by the patient (J0) and data from CGM devices over the last 3 months collected by the diabetologist, as part of care. | |
| Evaluate the impact of TCA on the glycemic profile of type 1 diabetic patients without eating disord | Correlation of self-documented questionnaires completed by the patient (J0) and data from CGM devices over the last 3 months collected by the diabetologist, as part of care. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Evaluation of the impact of TCA on the glycemic profile of patients with type 1 diabetes
The main objective of the study is to evaluate the impact of TCA on the glycemic profile of patients with type 1 diabetes. Time spent in and above target glycemic range over the past 3 months will be assessed in patients with an eating disorder (ED).
Measured: 3 months
Secondary outcomes (8)
Evaluate the impact of TCA in type 1 diabetic patients on HbA1c measurement
Comparison of blood measurements of HbA1c values between the group of type 1 diabetic patients with eating disorders and the group of type 1 diabetic patients without eating disorders. This measurement is performed by blood test as part of their standard care.
Measured: 1 day
Evaluate the impact of TCA in type 1 diabetic patients on complications of diabetes (GMI (glucose management indicator))
Comparison of the GMI (glucose management indicator) between the group of type 1 diabetic patients with eating disorders and the group of type 1 diabetic patients without eating disorders. This measurement is performed by blood test as part of their standard care.
Measured: 1 day
Evaluate the impact of TCA in type 1 diabetic patients on complications of diabetes (microangiopathic (diabetic retinopathy))
Comparison of the prevalence of microangiopathic complications (diabetic retinopathy) between the group of type 1 diabetic patients with eating disorders and the group of type 1 diabetic patients without eating disorders. This data is collected retrospectively from patients' medical records over a period of three months prior to inclusion.
Measured: 3 months
Evaluate the impact of TCA in type 1 diabetic patients on complications of diabetes (microangiopathic (diabetic neuropathy))
Comparison of the prevalence of microangiopathic complications (diabetic neuropathy) between the group of type 1 diabetic patients with eating disorders and the group of type 1 diabetic patients without eating disorders. This data is collected retrospectively from patients' medical records over a period of three months prior to inclusion.
Measured: 3 months
Evaluate the impact of TCA in type 1 diabetic patients on complications of diabetes (microangiopathic (diabetic nephropathy))
Comparison of the prevalence of microangiopathic complications (diabetic nephropathy) between the group of type 1 diabetic patients with eating disorders and the group of type 1 diabetic patients without eating disorders. This data is collected retrospectively from patients' medical records over a period of three months prior to inclusion.
Measured: 3 months
Evaluate the impact of TCA in type 1 diabetic patients on associated factors (anxiety)
The Hospital Anxiety and Depression Scale (HADS) is used as a screening tool for anxiety and depression levels, primarily in hospital settings or general practice. The HAD is a short questionnaire used to detect emotional disturbances in patients, without relying on physical symptoms (fatigue, insomnia, etc.) to avoid confusion with somatic illnesses. The questionnaire consists of 14 questions, divided into two subscales:
7 questions for anxiety (HADS-A) 7 questions for depression (HADS-D). Each question is scored from 0 to 3, according to the intensity of symptoms experienced in recent days. For each subscale (anxiety and depression), a score out of 21 is obtained: 0 to 7: no significant disorder 8 to 10: doubtful (borderline) 11 to 21: probable disorder (anxiety or depression)
Measured: 1 day
Evaluate the impact of TCA in type 1 diabetic patients on associated factors (depression)
The Hospital Anxiety and Depression Scale (HADS) is used as a screening tool for anxiety and depression levels, primarily in hospital settings or general practice. The HAD is a short questionnaire used to detect emotional disturbances in patients, without relying on physical symptoms (fatigue, insomnia, etc.) to avoid confusion with somatic illnesses. The questionnaire consists of 14 questions, divided into two subscales:
7 questions for anxiety (HADS-A) 7 questions for depression (HADS-D). Each question is scored from 0 to 3, according to the intensity of symptoms experienced in recent days. For each subscale (anxiety and depression), a score out of 21 is obtained: 0 to 7: no significant disorder 8 to 10: doubtful (borderline) 11 to 21: probable disorder (anxiety or depression)
Measured: 1 day
Assessment of time spent in and above target blood glucose levels over the past 3 months.
Comparison of time spent below target blood glucose levels over the last 3 months between the group of type 1 diabetic patients with eating disorders and the group of type 1 diabetic patients without eating disorders.
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Apr 2026
- Study start10 Jun 2022
- Primary completion31 May 2023
- Study completion1 Jun 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Eating Disorders in AdolescenceStudies of the same condition, open and under way.
- More trials run by University Hospital, RouenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 70 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Rouen
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- NAJATE NA ACHAMRAH, Professor, Study director, University Rouen Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07534059
- Sponsor's protocol ID
- 2022/059/OB
- Other IDs
- 2022-A00705-38
- Acronym
- DIAB-ED
- Status last verified
- Mar 2026
- First submitted
- 17 Mar 2026
- Last updated
- 16 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of Eating Disorders on the Glycemic Profile of Type 1 Diabetic Patients
- ClinicalTrials.gov ID
- NCT07534059
- Acronym / sponsor ID
- DIAB-ED / 2022/059/OB
- Conditions
- Eating Disorders in Adolescence
- Keywords
- type 1 diabetic patients
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 70 participants (actual)
- Lead sponsor
- University Hospital, RouenUniversity, hospital or other
- Study start
- 10 Jun 2022 (actual)
- Primary completion
- 31 May 2023 (actual)
- Study completion
- 1 Jun 2024 (actual)
- First posted
- 16 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Eating disorders (EDs), as classified by the American Psychiatric Association's DSM-5, have an estimated lifetime prevalence of 0.6% in the Caucasian adult population, with a male-to-female ratio of 1:8, and begin in 84% to 87% of cases between the ages of 15 and 25.
Anorexia nervosa (AN) is an eating disorder that represents a significant public health concern due to its impact on long-term morbidity and mortality. The incidence of AN is steadily increasing in many countries, particularly in France, with a prevalence of 2-3% among adolescents and young adults. A 10-year mortality rate of 5-10% has been reported, making AN the psychiatric disorder with the highest mortality rate. This predominantly female disorder (female-to-female ratio of 1:9) is defined by the persistent association of disordered eating behavior, distorted body image, and obsessions with weight and food, with detrimental health consequences. Anorexia nervosa (AN) exposes patients to numerous somatic and neuropsychiatric complications, which are poor prognostic factors. Its etiopathogenesis is multifactorial and involves environmental, psychological, genetic, and sociocultural factors. Bulimia nervosa (BN) is also associated with an intense fear of gaining weight. There is a disturbance of body image characterized by profound dissatisfaction with weight and physical appearance. BN is characterized by binge-eating episodes (consuming a large amount of food in a short period of time, associated with a feeling of loss of control) followed by inappropriate compensatory behaviors such as self-induced vomiting, misuse of laxatives, diuretics, or other medications; fasting; and excessive exercise. Individuals with bulimia nervosa generally have a subnormal body mass index (BMI), making diagnosis more difficult.
Type 1 diabetes is an autoimmune disease characterized by the destruction of the beta cells of the pancreatic islets of Langerhans, leading to a deficiency in insulin secretion. Generally, the diagnosis is made in childhood or adolescence, but late-diagnosed forms exist, forming an entity called latent autoimmune diabetes in adults (LADA), also known as type 1 diabetes. Diagnosis is made by measuring antibodies specific to type 1 diabetes: anti-GAD and anti-IA2 antibodies as the first-line tests, and anti-ZnT8 antibodies as a second-line test. Drug treatment primarily relies on continuous insulin administration via multiple daily injections or an insulin pump. Nutritional management is a cornerstone of treatment, playing a crucial role in glycemic control and the prevention of metabolic complications.
"Diabulimia" is a recent term describing a specific eating disorder in patients with type 1 diabetes. It is characterized by a voluntary restriction of insulin administration for the purpose of weight loss, at the expense of optimal glycemic control. This condition involves several complex factors (such as insulin injection, capillary blood glucose, emotions, and body image) that link diabetes management to the patient's mental health.
"Diabulimia" is not yet recognized as a distinct medical entity, lacks precise diagnostic criteria, and is difficult to detect. However, the serious consequences it entails, such as diabetic ketoacidosis in the short term and the chronic complications of hyperglycemia in the long term, make its screening essential.
Detailed description
Technological advances in the treatment of type 1 diabetes have been significant in recent years and have considerably improved the management of the disease.
Continuous glucose monitoring has radically changed the management of type 1 diabetes by empowering patients to self-manage and adjust their insulin therapy. Glucose monitoring methods have evolved considerably over the last few decades: from urine tests before the 1980s, to capillary blood glucose self-monitoring with a portable blood glucose meter introduced in 1978, to continuous glucose monitoring (CGM) methods that emerged in 1999.
Recently, CGMs have replaced capillary blood glucose meters. CGMs include sensors and transmitters that send blood glucose readings to a receiving system such as a meter, smartphone, or smartwatch, and potentially to a cloud service.
Currently in France, all diabetic patients on multi-injection or continuous insulin pump administration are eligible for reimbursement of a continuous glucose monitoring system allowing the measurement of interstitial glucose by wearing an interstitial glucose sensor. This study aims to evaluate blood glucose readings collected by two devices:
- Abbott FreeStyle Libre (FSL) is a flash interstitial glucose monitoring system where glucose is continuously monitored via intermittent scanning (ISGS). It is a standalone interstitial glucose sensor that collects glucose data by scanning the sensor.
- Dexcom is a real-time continuous glucose monitoring (RTGS) system. The reader provides a blood glucose reading every 5 minutes, along with a trend arrow and data collection over several hours (up to 24 hours).
These continuous glucose monitoring (CGM) methods allow blood glucose readings to be transmitted to an online platform that healthcare professionals can access. They can then analyze these readings remotely. This data analysis is assisted by algorithms that identify the time spent within, above, or below the target blood glucose level. Following the assessment by the healthcare professional, the patient can be contacted directly via the platform's instant messaging service.
In recent years, a link has been observed between type 1 diabetes (T1D) and eating disorders (EDs). Indeed, patients with T1D are at higher risk of developing an ED than the general population. This is partly explained by the fact that particular attention is paid to the dietary and nutritional management of T1D patients from the moment of their diabetes diagnosis, in order to allow for better glycemic control. Eating disorders in patients with type 1 diabetes (T1D) can lead to potentially serious complications. In the short term, they increase the likelihood of diabetic ketoacidosis resulting from hyperglycemia not corrected by adequate insulin administration. Hospitalization rates and length of stay are also significantly higher in patients with both T1D and an eating disorder. In the long term, they can lead to a higher prevalence of microvascular complications such as diabetic retinopathy (with a 2.5-fold increased risk), microalbuminuria, and diabetic neuropathy. Higher mortality has also been demonstrated in these patients: a mortality rate of 4.06% for patients with T1D, 8.86% for patients with anorexia nervosa, and 14.5% for patients with both conditions.
Few studies have investigated the association between T1D and eating disorders. These studies are older, have small sample sizes, and focus on only one type of eating disorder. Within the framework of this project, the SCOFF questionnaire will be used to screen for restrictive (anorexia nervosa) and compulsive (bulimia) eating disorders. Glycemic control will be assessed through the analysis of CGM data. No study has used this innovative tool to evaluate the impact of eating disorders on type 1 diabetes.
The aim is also to change healthcare professionals' approach to eating disorders by screening for them regularly and early to prevent chronicity and short- and medium-term complications. These results could contribute to establishing specific recommendations regarding the screening for eating disorders in the management of patients with type 1 diabetes, and for appropriate multidisciplinary care.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Evaluate the impact of TCA on the glycemic profile of type 1 diabetic patients with eating disorder | – | –Correlation of self-documented questionnaires completed by the patient (J0) and data from CGM devices over the last 3 months collected by the diabetologist, as part of care. |
| Evaluate the impact of TCA on the glycemic profile of type 1 diabetic patients without eating disord | – | –Correlation of self-documented questionnaires completed by the patient (J0) and data from CGM devices over the last 3 months collected by the diabetologist, as part of care. |
Who may qualify
- Ages
- 18 to 40 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- type 1 diabetic patients
Key inclusion criteria (8 listed)
- Female patients
- Patients aged 18 to 40 years
- Patients diagnosed with type 1 diabetes (positive for anti-GAD, anti-IA2, and anti-ZnT8 antibodies)
- Patients on insulin therapy alone (basal-bolus regimen or insulin pump)
- Patients using a continuous glucose monitoring device such as an FSL or DEXCOM
Key exclusion criteria (5 listed)
- Patients taking antidiabetic medication other than insulin therapy alone
- Patients with limited understanding of spoken or written French
- Individuals deprived of their liberty by an administrative or judicial decision, or individuals subject to legal protection measures for adults
- Individuals under guardianship, conservatorship, or other protective supervision
- Pregnant or breastfeeding women
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Evaluation of the impact of TCA on the glycemic profile of patients with type 1 diabetes
Time frame: 3 months
The main objective of the study is to evaluate the impact of TCA on the glycemic profile of patients with type 1 diabetes. Time spent in and above target glycemic range over the past 3 months will be assessed in patients with an eating disorder (ED).
8 secondary outcomes
Evaluate the impact of TCA in type 1 diabetic patients on HbA1c measurement
Time frame: 1 day
Evaluate the impact of TCA in type 1 diabetic patients on complications of diabetes (GMI (glucose management indicator))
Time frame: 1 day
Evaluate the impact of TCA in type 1 diabetic patients on complications of diabetes (microangiopathic (diabetic retinopathy))
Time frame: 3 months
Evaluate the impact of TCA in type 1 diabetic patients on complications of diabetes (microangiopathic (diabetic neuropathy))
Time frame: 3 months
Evaluate the impact of TCA in type 1 diabetic patients on complications of diabetes (microangiopathic (diabetic nephropathy))
Time frame: 3 months
Evaluate the impact of TCA in type 1 diabetic patients on associated factors (anxiety)
Time frame: 1 day
Evaluate the impact of TCA in type 1 diabetic patients on associated factors (depression)
Time frame: 1 day
Assessment of time spent in and above target blood glucose levels over the past 3 months.
Time frame: 3 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Apr 2026.
- Individual participant dataSharing planned: No
Related trials for Eating Disorders in Adolescence
Not yet recruiting
Development, Implementation, and Evaluation of the HADAS Program for the Prevention of Eating Disorders in Adolescent Female Athletes, Coaches, and Families.
Eating Disorders, Body Image Dissatisfaction
Active, not recruiting
Project VIBE: Virtual Intervention for Binge Eating in Adolescents
Obesity, Binge-Eating Disorder
Not yet recruiting
Effectiveness of a 10-week Multicomponent Intervention Combined With Parent Education on Binge Eating Behavior in Children and Adolescents
Binge Eating Disorder, Binge Eating
Recruiting
Cerebellar tDCS Stimulation in Children and Adult Women With Anorexia Nervosa Disorder
Anorexia Nervosa
Not yet recruiting
QAIAx - SGI/SI Smart Health Cities: Microcity Enclave Program (Quantum SI/AGI Agency a/k/a AI City Hall Project - UPSTO App Nos. 64/074,526, 64/063,557, 64/105,164, 63/903,181, 63/729,428, 64/125,360; USPTO EO 9424 Assignment ID: 2101042 / ARN: REEL/FRAME: 76481/0026 - OUSD-R&E, Department of War)
Asperger's Disorder, Asperger Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
NAJATE NA ACHAMRAH, Professor study director
University Rouen Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Eating Disorders in Adolescence, run by University Hospital, Rouen at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Evaluation of the impact of TCA on the glycemic profile of patients with type 1 diabetes (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Apr 2026.